DS 5361
Alternative Names: DS-5361; DS-5361bLatest Information Update: 26 Nov 2025
At a glance
- Originator Daiichi Sankyo Company
- Class Antineoplastics; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 19 Nov 2025 Phase-I clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) in Japan (unspecified route) (jRCT2031250489)
- 19 Nov 2025 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Recurrent) in Japan (unspecified route) (jRCT2031250489)
- 10 Sep 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Recurrent, Inoperable/Unresectable, Combination therapy) in USA (unspecified route) (NCT07182591)